Like studies in melanoma, where BRAF inhibitor monotherapy shows rapid but transient MAPK pathway inhibition, PLX4720 treatment in glioma cell lines (M-38, DBTRG-05MG and NMC-G1) did not suppress MAPK pathway signaling in a durable way. The gene discussed is BRAF; the disease is central nervous system cancer.